© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 2, 136-142,
January 19, 2000
© 2000 Oxford University Press
Cost of Care for Patients in Cancer Clinical Trials
Affiliation of authors: Division of Research, Kaiser Permanente, Northern California, Oakland.
Correspondence to: Bruce H. Fireman, M.A., Division of Research, Kaiser Permanente, 3505 Broadway, Oakland, CA 94611 (e-mail: bhf{at}dor.kaiser.org).
BACKGROUND: Information on the costs of medical care for patients enrolled in clinical trials is needed by policymakers evaluating ways to facilitate clinical research in a managed care environment. We examined the direct costs of medical care for patients enrolled in cancer clinical trials at a large health maintenance organization (HMO). METHODS: Costs for 135 patients who entered 22 cancer clinical trials (including 12 breast cancer trials) at Kaiser Permanente in Northern California, from 1994 through 1996 were compared with costs for 135 matched control subjects who were not enrolled in such trials. Cancer registry data and medical charts were used in matching the control subjects to the trial enrollees with respect to cancer site, stage, date of diagnosis, age, sex, and trial eligibility. The direct costs of medical care were compared between trial enrollees and the control subjects for a 1-year period, with data on costs and utilization of services obtained from Kaiser Permanente databases and medical charts. RESULTS: Mean 1-year costs for the enrollees in trials were 10% higher than those for the control subjects ($17 003 per enrollee compared with $15 516 per control subject; two-sided P = .011). The primary component of this difference was a $1376 difference in chemotherapy costs ($4815 per trial enrollee versus $3439 per control subject; two-sided P<.001). Costs for the 11 enrollees in trials that had a bone marrow transplant (BMT) arm were approximately double the costs for their matched control subjects (borderline significance: two-sided P= .054). The $15 041 mean cost for the enrollees in trials without BMT was similar to the $15 186 mean cost for their matched control subjects. CONCLUSIONS: Participation in cancer clinical trials at a large HMO did not result in substantial increases in the direct costs of medical care.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. S. Perrin and F. J G. Lopez Incremental Drug Treatment Cost in HIV-Positive Patients in Industry-Sponsored Clinical Trials Ann. Pharmacother., November 1, 2008; 42(11): 1586 - 1591. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Go, W. Y. Lee, J. Yang, J. C. Lo, and J. H. Gurwitz Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA, November 1, 2006; 296(17): 2105 - 2111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Go, J. Yang, L. M. Ackerson, K. Lepper, S. Robbins, B. M. Massie, and M. G. Shlipak Hemoglobin Level, Chronic Kidney Disease, and the Risks of Death and Hospitalization in Adults With Chronic Heart Failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study Circulation, June 13, 2006; 113(23): 2713 - 2723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Go, C. Iribarren, M. Chandra, P. V. Lathon, S. P. Fortmann, T. Quertermous, M. A. Hlatky, and for the Atherosclerotic Disease, Vascular Function Statin and beta-blocker therapy and the initial presentation of coronary heart disease. Ann Intern Med, February 21, 2006; 144(4): 229 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Go, G. M. Chertow, D. Fan, C. E. McCulloch, and C.-y. Hsu Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization N. Engl. J. Med., September 23, 2004; 351(13): 1296 - 1305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. Hillner Barriers to Clinical Trial Enrollment: Are State Mandates the Solution? J Natl Cancer Inst, July 21, 2004; 96(14): 1048 - 1049. [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Sherman, D. M. Rubin, E. Venkatraman, G. K. Schwartz, V. A. Miller, M. H. Radzyner, H. S. Ruchlin, D. Spriggs, and D. G. Pfister Using Patients As Their Own Controls for Cost Evaluation of Phase I Clinical Trials J. Clin. Oncol., April 1, 2004; 22(7): 1308 - 1314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Wright and M. N. Levine Researching the Cost of Research J. Clin. Oncol., November 15, 2003; 21(22): 4081 - 4082. [Full Text] [PDF]
|
|
|
|
|
|
D. P. Goldman, S. H. Berry, M. S. McCabe, M. L. Kilgore, A. L. Potosky, M. L. Schoenbaum, M. Schonlau, J. C. Weeks, R. Kaplan, and J. J. Escarce Incremental Treatment Costs in National Cancer Institute-Sponsored Clinical Trials JAMA, June 11, 2003; 289(22): 2970 - 2977. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Yates Clinicians in Community Practice Are Major Contributors to Clinical Trials in Cancer Prevention, Early Detection, and Treatment CA Cancer J Clin, March 1, 2003; 53(2): 69 - 72. [Full Text]
|
|
|
|
|
|
S. D. Ramsey, C. M. Moinpour, L. C. Lovato, J. J. Crowley, P. Grevstad, C. A. Presant, S. E. Rivkin, K. Kelly, and D. R. Gandara Economic Analysis of Vinorelbine Plus Cisplatin Versus Paclitaxel Plus Carboplatin for Advanced Non-Small-Cell Lung Cancer J Natl Cancer Inst, February 20, 2002; 94(4): 291 - 297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Roche, N. Paul, B. Smuck, M. Whitehead, B. Zee, J. Pater, M.-A. Hiatt, and H. Walker Factors Affecting Workload of Cancer Clinical Trials: Results of a Multicenter Study of the National Cancer Institute of Canada Clinical Trials Group J. Clin. Oncol., January 15, 2002; 20(2): 545 - 556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Bennett, J. R. Adams, K. S. Knox, A. M. Kelahan, S. M. Silver, and J. S. Bailes Clinical Trials: Are They a Good Buy? J. Clin. Oncol., December 1, 2001; 19(23): 4330 - 4339. [Abstract] [Full Text]
|
|
|
|
|
|
D. P. Goldman, M. L. Schoenbaum, A. L. Potosky, J. C. Weeks, S. H. Berry, J. J. Escarce, B. A. Weidmer, M. L. Kilgore, N. Wagle, J. L. Adams, et al. Measuring the Incremental Cost of Clinical Cancer Research J. Clin. Oncol., January 1, 2001; 19(1): 105 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Presant Patient Costs on Clinical Trials J Natl Cancer Inst, September 6, 2000; 92(17): 1441 - 1442. [Full Text] [PDF]
|
|
|
|
|
|
C. L. Bennett, T. J. Stinson, V. Vogel, L. Robertson, D. Leedy, P. O'Brien, J. Hobbs, T. Sutton, J. C. Ruckdeschel, T. N. Chirikos, et al. Evaluating the Financial Impact of Clinical Trials in Oncology: Results From a Pilot Study From the Association of American Cancer Institutes/Northwestern University Clinical Trials Costs and Charges Project J. Clin. Oncol., August 15, 2000; 18(15): 2805 - 2810. [Abstract] [Full Text] [PDF]
|
|